Genistein: Its role in metabolic diseases and cancer

Critical Reviews in Oncology/Hematology

Volumn 119, Issue , 2017, Pages 13-22

  Mukund, Vidya ^a   Mukund, Dhruv ^b   Sharma, Vinay ^a   Mannarapu, Mastan ^c   Alam, Afroz ^a  

^a BANASTHALI UNIVERSITY   (India)

^b PACE College   (India)

^c DRAVIDIAN UNIVERSITY   (India)

Author keywords

Adipogenesis; Cancer; Genistein; Insulin; Metabolic diseases

Indexed keywords

CORTICOTROPIN; ERLOTINIB; GEMCITABINE; GENISTEIN; HYDROCORTISONE; INSULIN;

ADIPOGENESIS; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; EPIGENETICS; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; MALIGNANT NEOPLASM; METABOLIC DISORDER; METASTASIS; NONHUMAN; PHARMACODYNAMICS; REVIEW; RHEUMATOID ARTHRITIS; STEREOCHEMISTRY; TUMOR INVASION; ANIMAL; CHEMISTRY; NEOPLASM;

ANIMALS; GENISTEIN; HUMANS; METABOLIC DISEASES; NEOPLASMS;

EID: 85032703044     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2017.09.004     Document Type: Review

References (156)

1. Adlercreutz, H., van der Wildt, J., Kinzel, J., et al. Lignan and isoflavonoid conjugates in human urine. J. Steroid Biochem. Mol. Biol. 52 (1995), 97–103.
2. Aggarwal, B.B., Gehlot, P., Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr. Opin. Pharmacol. 9 (2009), 351–369.
3. Aggarwal, B.B., Shishodia, S., Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006), 1397–1421.
4. Aggarwal, B.B., Shishodia, S., Suppression of the nuclear factor B activation pathway by spice derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci., 2016, 434–441 (20041030).
5. Aggarwal, B.B., Sundaram, C., Malani, N., et al. Curcumin: the Indian solid gold. Mol. Targets Ther. Curcumin Health Dis., 2007, 1–75.
6. Andersen, Ø.M., Markham, K.R., Flavonoids: Chemistry, Biochemistry and Applications. 2006, CRC Press.
7. Andrade, J.E., Twaddle, N.C., Helferich, W.G., et al. Absolute bioavailability of isoflavones from soy protein isolate-containing food in female BALB/c mice. J. Agric. Food Chem. 58 (2010), 4529–4536.
8. Ascencio, C., Torres, N., Isoard-Acosta, F., et al. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J. Nutr., 134, 2004, 522.
9. Ballard-Barbash, R., Schatzkin, A., Carter, C.L., et al. Body fate dwistribution and Breast cancer in the framingham study. J. Natl. Cancer Inst., 82, 1990, 286.
10. Banerjee, S., Li, Y., Wang, Z., et al. Multi-targeted therapy of cancer by genistein. Cancer Lett. 269 (2008), 226–242.
11. Basak, S., Pookot, D., Noonan, E.J., et al. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol. Cancer Ther., 7, 2008, 3195.
12. Baud, V., Karin, M., Is NF- B a good target for cancer therapy: hopes and pitfalls. Nat. Rev. Drug Discov. 8 (2009), 33–40.
13. Bazuine, M., van den Broek, P.J.A., Maassen, J., Genistein directly inhibits GLUT4-mediated glucose uptake in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 326 (2005), 511–514.
14. Bektic, J., Guggenberger, R., Eder, I.E., et al. Molecular effects of the isoflavonoid genistein in prostate cancer. Clin. Genitourin. Cancer 4 (2005), 124–129.
15. Bergan, R., Kyle, E., Nguyen, P., et al. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-l-integrin. Clin. Exp. Metastasis 14 (1996), 389–398.
16. Budak, E., Fernández Sánchez, M., Bellver, J., et al. Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system. Fertil. Steril. 85 (2006), 1563–1581.
17. Busby, M.G., Jeffcoat, A.R., Bloedon, L.T., et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr. 75 (2002), 126–136.
18. Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases. Nature-London, 2000, 249–257.
19. Cassidy, A., Factors affecting the bioavailability of soy isoflavones in humans. J. AOAC Int. 89 (2006), 1182–1188.
20. Chang, Y.-C., Nair, M.G., Metabolism of daidzein and genistein by intestinal bacteria. J. Nat. Prod. 58 (1995), 1892–1896.
21. Chang, H.C., Churchwell, M.I., Delclos, K.B., et al. Mass spectrometric determination of genistein tissue distribution in diet-exposed Sprague-Dawley rats. J. Nutr. 130 (2000), 1963–1970.
22. Choi, J.S., Song, J., Effect of genistein on insulin resistance, renal lipid metabolism, and antioxidative activities in ovariectomized rats. Nutrition 25 (2009), 676–685.
23. Choi, Y.H., Lee, W.H., Park, K.Y., et al. P53 independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Cancer Sci. 91 (2000), 164–173.
24. Cohen, J.J., Apoptosis: mechanisms of life and death in the immune system. J. Allergy Clin. Immunol. 103 (1999), 548–554.
25. Coldham, N.G., Sauer, M.J., Pharmacokinetics of [14C] genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. Toxicol. Appl. Pharmacol. 164 (2000), 206–215.
26. Coldham, N.G., Zhang, A.-Q., Key, P., et al. Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity. Eur. J. Drug Metab. Pharmacokinet. 27 (2002), 249–258.
27. Cornwell, T., Cohick, W., Raskin, I., Dietary phytoestrogens and health. Phytochemistry 65 (2004), 995–1016.
28. Coussens, L.M., Werb, Z., Inflammation and cancer. Nature-London, 2002, 860–867.
29. Harris, R., Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17 (2009), 55–67.
30. Dannenberg, A.J., Subbaramaiah, K., Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 4, 2003, 431.
31. Davis, J.N., Kucuk, O., Sarkar, F.H., Genistein inhibits NF-kB activation in prostate cancer cells. Nutr. Cancer 35 (1999), 167–174.
32. Eferl, R., Wagner, E.F., AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3 (2003), 859–868.
33. El Touny, L.H., Banerjee, P.P., Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res., 69, 2009, 3695.
34. El-Rayes, B.F., Ali, S., Ali, I.F., et al. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor- B. Cancer Res., 66, 2006, 10553.
35. Engelman, J.A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9 (2009), 550–562.
36. Farina, A., Sekizawa, A., Purwosunu, Y., et al. Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls. Prenat. Diagn. 26 (2006), 1115–1120.
37. Ferenc, P., Solár, P., Kleban, J., et al. Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. J. Photochem. Photobiol., B 98 (2010), 25–34.
38. Fisher, R.I., Bernstein, S.H., Kahl, B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol., 24, 2006, 4867.
39. Ford, E.S., Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care, 28, 2005, 2745.
40. Friedl, P., Wolf, K., Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3 (2003), 362–374.
41. Genistin, Walter E., (An isoflavone glucoside) and its aglucone, genistein, from soybeans. J. Am. Chem. Soc. 63 (1941), 3273–3276.
42. Genolet, R., Wahli, W., Michalik, L., PPARs as drug targets to modulate inflammatory responses?. Curr. Drug Targets-Inflammation Allergy 3 (2004), 361–375.
43. Gescher, A., Pastorino, U., Plummer, S.M., et al. Suppression of tumour development by substances derived from the diet—mechanisms and clinical implications. Br. J. Clin. Pharmacol. 45 (1998), 1–12.
44. Gong, L., Li, Y., Nedeljkovic-Kurepa, A., et al. Inactivation of NF- B by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22 (2003), 4702–4709.
45. Gu, L., House, S.E., Prior, R.L., et al. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J. Nutr. 136 (2006), 1215–1221.
46. Gu, Y., Zhu, C.F., Dai, Y.L., et al. Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma. World J. Gastroenterol., 15, 2009, 4952.
47. Hämäläinen, M., Nieminen, R., Vuorela, P., et al. Anti-Inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STATand NF-B activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-B activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm., 2007, 2007, 1.
48. Hillman, G.G., Wang, Y., Kucuk, O., et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol. Cancer Ther., 3, 2004, 1271.
49. Huang, X., Chen, S., Xu, L., et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res., 65, 2005, 3470.
50. Hulley, S., Grady, D., Bush, T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 280, 1998, 605.
51. Hur, H.-G., Beger, R.D., Heinze, T.M., et al. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. Arch. Microbiol. 178 (2002), 8–12.
52. Ismail, I.A., Kang, K.S., Lee, H.A., et al. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur. J. Pharmacol. 575 (2007), 12–20.
53. Izukawa, T., Nakajima, M., Fujiwara, R., et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab. Dispos. 37 (2009), 1759–1768.
54. Jawaid, K., Crane, S.R., Nowers, J.L., et al. Long-term genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors. J. Steroid Biochem. Mol. Biol. 120 (2010), 164–171.
55. Jernås, M., Palming, J., Sjöholm, K., et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J., 20, 2006, 1540.
56. Jinno, H., Tanaka-Kagawa, T., Ohno, A., et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos., 31, 2003, 398.
57. Jonas, J.C., Plant, T., Gilon, P., et al. Multiple effects and stimulation of insulin secretion by the tyrosine kinase inhibitor genistein in normal mouse islets. Br. J. Pharmacol., 114, 1995, 872.
58. Kaefer, C.M., Milner, J.A., The role of herbs and spices in cancer prevention. J. Nutr. Biochem. 19 (2008), 347–361.
59. Kano, M., Takayanagi, T., Harada, K., et al. Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J. Nutr. 136 (2006), 2291–2296.
60. Ke, Y., Masahiro, H., Dennis, S., Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div, 2006.
61. Kikuno, N., Shiina, H., Urakami, S., et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int. J. Cancer 123 (2008), 552–560.
62. Kim, J.K., Diehl, J.A., Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 220 (2009), 292–296.
63. Kim, M., Han, J., Absolute configuration of (−)-2-(4-hydroxyphenyl) propionic acid: stereochemistry of soy isoflavone metabolism. Bull. Korean Chem. Soc. 35 (2014), 1883–1886.
64. Kim, M., Han, J., Chiroptical study and absolute configuration of (–)–O-DMA produced from daidzein metabolism. Chirality 26 (2014), 434–437.
65. Kim, H., Xu, J., Su, Y., et al. Actions of the soy phytoestrogen genistein in models of human chronic disease: potential involvement of transforming growth factor beta. Biochem. Soc. Trans. 29 (2001), 216–221.
66. Kim, S., Shin, H.J., Kim, S.Y., et al. Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPAR [alpha]. Mol. Cell. Endocrinol. 220 (2004), 51–58.
67. Kim, S.H., Kim, Y.B., Jeon, Y.T., et al. Genistein inhibits cell growth by modulating various mitogen activated protein kinases and AKT in cervical cancer cells. Ann. N. Y. Acad. Sci. 1171 (2009), 495–500.
68. King, R.A., Bursill, D.B., Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am. J. Clin. Nutr. 67 (1998), 867–872.
69. King-Batoon, A., Leszczynska, J.M., Klein, C.B., Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen. 49 (2008), 36–45.
70. Kousidou, O.C., Tzanakakis, G., Karamanos, N., Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells. Mini Rev. Med. Chem. 6 (2006), 331–337.
71. Krammer, P.H., CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71 (1998), 163–210.
72. Kuhn, D.J., Chen, Q., Voorhees, P.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110 (2007), 3281–3290.
73. Kumi-Diaka, J., Hassanhi, M., Merchant, K., et al. Influence of genistein isoflavone on matrix metalloproteinase-2 expression in prostate cancer cells. J. Med. Food 9 (2006), 491–497.
74. Kurkela, M., Garcı́a-Horsman, J.A., Luukkanen, L., et al. Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs) UGT1A9 is more resistant to detergent inhibition than the other UGTS and was purified as an active dimeric enzyme. J. Biol. Chem. 278 (2003), 3536–3544.
75. Kyle, E., Neckers, L., Takimoto, C., et al. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol. Pharmacol., 51, 1997, 193.
76. Larkin, T., Price, W.E., Astheimer, L., The key importance of soy isoflavone bioavailability to understanding health benefits. Crit. Rev. Food Sci. Nutr. 48 (2008), 538–552.
77. Lee, Y.K., Park, O.J., Soybean isoflavone genistein regulates apoptosis through NF-[kappa] B dependent and independent pathways. Exp. Toxicol. Pathol., 2011.
78. Lee, M.J., Kim, Y.S., Kummar, S., et al. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol., 20, 2008, 639.
79. Li, Y., Sarkar, F.H., Inhibition of nuclear factor B activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res., 8, 2002, 2369.
80. Liu, W., Ahmad, S., Reinmuth, N., et al. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5 (2000), 323–328.
81. Liu, J., Zheng, X., Yin, F., et al. Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int. J. Dev. Neurosci. 24 (2006), 419–424.
82. Liu, P., Cheng, H., Roberts, T.M., et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8 (2009), 627–644.
83. MacGregor, C., Canney, P., Patterson, G., et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur. J. Cancer 41 (2005), 708–714.
84. Mackowiak, P., Nogowski, L., Nowak, K., Effect of isoflavone genistein on insulin receptors in perfused liver of ovariectomized rats. J. Recept. Signal Transduct. 19 (1999), 283–292.
85. Maffeis, C., Silvagni, D., Bonadonna, R., et al. Fat cell size, insulin sensitivity, and inflammation in obese children. J. Pediatr. 151 (2007), 647–652.
86. Manach, C., Williamson, G., Morand, C., et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 81 (2005), 230S–242S.
87. Masharani, U., Goldfine, I.D., Youngren, J.F., Influence of gender on the relationship between insulin sensitivity, adiposity, and plasma lipids in lean nondiabetic subjects. Metabolism 58 (2009), 1602–1608.
88. Matarese, G., La Cava, A., Sanna, V., et al. Balancing susceptibility to infection and autoimmunity: a role for leptin?. Trends Immunol. 23 (2002), 182–187.
89. Matthews, C.P., Colburn, N.H., Young, M.R., AP-1 a target for cancer prevention. Curr. Cancer Drug Targets 7 (2007), 317–324.
90. Meng, R.D., Shelton, C.C., Li, Y.M., et al. Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res., 69, 2009, 573.
91. Mesiano, S., Katz, S.L., Lee, J.Y., et al. Phytoestrogens alter adrenocortical function: genistein and daidzein suppress glucocorticoid and stimulate androgen production by cultured adrenal cortical cells. J. Clin. Endocrinol. Metab., 84, 1999, 2443.
92. Mi kus, K., Madeja, Z., Genistein inhibits the contact-stimulated migration of prostate cancer cells. Cell. Mol. Biol. Lett. 12 (2007), 348–361.
93. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004), 221–230.
94. Mommsen, T.P., Vijayan, M.M., Moon, T.W., Cortisol in teleosts: dynamics, mechanisms of action, and metabolic regulation. Rev. Fish Biol. Fish. 9 (1999), 211–268.
95. Morris, P.E., Olmstead, L.E., Howard-Carroll, A.E., et al. In vitro and in vivo effects of genistein on murine alveolar macrophage TNF production. Inflammation 23 (1999), 231–239.
96. Mueller, S.O., Simon, S., Chae, K., et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor (ER) and ER in human cells. Toxicol. Sci., 80, 2004, 14.
97. Nagaraju, G.P., Reproductive regulators in decapod crustaceans: an overview. J. Exp. Biol. 214 (2011), 3–16.
98. Nakamura, Y., Yogosawa, S., Izutani, Y., et al. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol. Cancer, 8, 2009, 100.
99. Nauclér, C., Grinstein, S., Sundler, R., et al. Signaling to localized degranulation in neutrophils adherent to immune complexes. J. Leukoc. Biol., 71, 2002, 701.
100. Nielsen, I.L.F., Williamson, G., Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr. Cancer 57 (2007), 1–10.
101. Nilsson, S., Kuiper, G., Gustafsson, J.A.E.R., [beta] A novel estrogen receptor offers the potential for new drug development. Trends Endocrinol. Metab. 9 (1998), 387–395.
102. Niwa, T., Yokoyama, T., Osawa, S.-i., Effect of the genistein metabolite on leptin secretion in murine adipocytes in vitro. Food Chem. 138 (2013), 122–125.
103. Nogowski, L., Nowak, K., Kaczmarek, P., et al. The influence of coumestrol, zearalenone, and genistein administration on insulin receptors and insulin secretion in ovariectomized rats. J. Recept. Signal Transduct. 22 (2002), 449–457.
104. Oh, H.Y., Leem, J., Yoon, S.J., et al. Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor. Biochem. Biophys. Res. Commun. 393 (2010), 319–324.
105. Ohno, H., Suzuki, C., Fukumoto, K., et al. Electron transfer process of poly (ethylene oxide)-modified cytochrome c in imidazolium type ionic liquid. Chem. Lett. 32 (2003), 450–451.
106. Okuno, A., Tamemoto, H., Tobe, K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest., 101, 1998, 1354.
107. Ouyang, G., Yao, L., Ruan, K., et al. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol. Int. 33 (2009), 1237–1244.
108. Overall, C., Kleifeld, O., Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94 (2006), 941–946.
109. Page-McCaw, A., Ewald, A.J., Werb, Z., Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8 (2007), 221–233.
110. Park, S.J., Kim, M.J., Kim, Y.K., et al. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. Cancer Lett. 292 (2010), 54–63.
111. Park, H.-Y., Kim, M., Han, J., Stereospecific microbial production of isoflavanones from isoflavones and isoflavone glucosides. Appl. Microbiol. Biotechnol. 91 (2011), 1173–1181.
112. Peng, J.H., Zhu, J.D., Mi, M.T., et al. Prepubertal genistein exposure affects erbB2/Akt signal and reduces rat mammary tumorigenesis. Eur. J. Cancer Prev., 19, 2010, 110.
113. Penza, M., Montani, C., Romani, A., et al. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology 147 (2006), 5740–5751.
114. Perraudin, V., Delarue, C., Lefebvre, H., et al. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J. Clin. Endocrinol. Metab., 76, 1993, 1522.
115. Pike, C.J., Estrogen modulates neuronal bcl xl expression and amyloid induced apoptosis. J. Neurochem. 72 (1999), 1552–1563.
116. Polak, P., Hall, M.N., mTORC2 caught in a SINful Akt. Developmental cell 11 (2006), 433–434.
117. Puli, S., Lai, J.C.K., Bhushan, A., Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J. Neurooncol. 79 (2006), 135–142.
118. Raffoul, J., Wang, Y., Kucuk, O., et al. Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer, 6, 2006, 107.
119. Ramos, E., Olivos-Garcia, A., Nequiz, M., et al. Entamoeba histolytica: apoptosis induced in vitro by nitric oxide species. Exp. Parasitol. 116 (2007), 257–265.
120. Ramos, S., Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J. Nutr. Biochem. 18 (2007), 427–442.
121. Relic, B., Zeddou, M., Desoroux, A., et al. Genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts. Lab. Invest. 89 (2009), 811–822.
122. Riches, Z., Stanley, E.L., Bloomer, J.C., et al. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT pie. Drug Metab. Dispos. 37 (2009), 2255–2261.
123. Rossouw, J.E., Prentice, R.L., Manson, J.A.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297, 2007, 1465.
124. Sarkar, F.H., Li, Y., Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res., 66, 2006, 3347.
125. Sawai, H., Okada, Y., Funahashi, H., et al. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol. Cancer, 4, 2005, 37.
126. Setchell, K.D., Brown, N.M., Desai, P., et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 131 (2001), 1362S–1375S.
127. Sethi, G., Tergaonkar, V., Potential pharmacological control of the NF-[kappa] B pathway. Trends Pharmacol. Sci. 30 (2009), 313–321.
128. Sethi, G., Sung, B., Aggarwal, B.B., Nuclear factor-{kappa} B activation: from bench to bedside. Exp. Biol. Med., 233, 2008, 21.
129. Shelnutt, S.R., Cimino, C.O., Wiggins, P.A., et al. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiol. Prev. Biomark. 9 (2000), 413–419.
130. Shelnutt, S.R., Cimino, C.O., Wiggins, P.A., et al. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am. J. Clin. Nutr. 76 (2002), 588–594.
131. Sieg, D.J., Hauck, C.R., Ilic, D., et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2 (2000), 249–256.
132. Skogseth, H., Larsson, E., Halgunset, J., The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase. APMIS 114 (2006), 61–66.
133. Smith, R., Tiesinga, J., Shah, N., et al. Genistein inhibits insulin-stimulated glucose transport and decreases immunocytochemical labeling of GLUT4 carboxyl-terminus without affecting translocation of GLUT4 in isolated rat adipocytes: additional evidence of GLUT4 activation by insulin. Arch. Biochem. Biophys. 300 (1993), 238–246.
134. Stephenson, G.D., Rose, D.P., Breast cancer and obesity: an update. Nutr. Cancer 45 (2003), 1–16.
135. Su, Y., Simmen, R., Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates–catenin signaling in mammary epithelial cells. Carcinogenesis, 30, 2009, 331.
136. Szkudelska, K., Nogowski, L., Genistein–a dietary compound inducing hormonal and metabolic changes. J. Steroid Biochem. Mol. Biol. 105 (2007), 37–45.
137. Taylor, C.K., Levy, R.M., Elliott, J.C., et al. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr. Rev. 67 (2009), 398–415.
138. Upadhyay, S., Neburi, M., Chinni, S.R., et al. Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21WAF1. Clin. Cancer Res., 7, 2001, 1782.
139. Valle, J., Wasan, H., Palmer, D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl. J. Med. 362 (2010), 1273–1281.
140. Valles, S.L., Dolz-Gaiton, P., Gambini, J., et al. Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR [gamma] expression in cultured astrocytes. Brain Res. 1312 (2010), 138–144.
141. Verdrengh, M., Jonsson, I., Holmdahl, R., et al. Genistein as an anti-inflammatory agent. Inflamm. Res. 52 (2003), 341–346.
142. Wang, K.X., Denhardt, D.T., Osteopontin: role in immune regulation and stress responses. Cytokine Growth Fact. Rev. 19 (2008), 333–345.
143. Wang, L.M., Ren, D.M., Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev. Med. Chem. 10 (2010), 1058–1070.
144. Wang, Z., Li, Y., Banerjee, S., et al. Down regulation of Notch 1 and Jagged 1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF B signaling pathways. J. Cell. Biochem. 109 (2010), 726–736.
145. Wannamethee, S.G., Shaper, A.G., Lennon, L., et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med., 165, 2005, 2644.
146. Wullschleger, S., Loewith, R., Hall, M.N., TOR signaling in growth and metabolism. Cell 124 (2006), 471–484.
147. Xu, L., Bergan, R.C., Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor β-mediated activation of mitogen-activated protein kinase-activated protein kinase 2–27-kDa heat shock protein pathway. Mol. Pharmacol., 70, 2006, 869.
148. Yamauchi, K., Ishihara, A., Fukazawa, H., et al. Competitive interactions of chlorinated phenol compounds with 3, 3’ 5-triiodothyronine binding to transthyretin: detection of possible thyroid-disrupting chemicals in environmental waste water. Toxicol. Appl. Pharmacol. 187 (2003), 110–117.
149. Yan, G.R., Xiao, C.L., He, G.W., et al. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics 10 (2010), 976–986.
150. Yang, Z., Zhu, W., Gao, S., et al. Simultaneous determination of genistein and its four phase II metabolites in blood by a sensitive and robust UPLC–MS/MS method: application to an oral bioavailability study of genistein in mice. J. Pharm. Biomed. Anal. 53 (2010), 81–89.
151. Yellayi, S., Zakroczymski, M., Selvaraj, V., et al. The phytoestrogen genistein suppresses cell-mediated immunity in mice. J. Endocrinol., 176, 2003, 267.
152. Yong, V.W., Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6 (2005), 931–944.
153. Yu, X., Zhu, J., Mi, M., et al. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med. Oncol., 2010, 1–9.
154. Zhang, B., Shi, Z.L., Liu, B., et al. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-[kappa] B. Anticancer Drugs, 21, 2010, 288.
155. Zhang, R., Pan, X., Huang, Z., et al. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One, 6, 2011, e23831.
156. Zhou, S., Hu, Y., Zhang, B., et al. Dose-dependent absorption, metabolism, and excretion of genistein in rats. J. Agric. Food Chem. 56 (2008), 8354–8359.